Word

YOCHANRA

Status

Pending

Status Code

686

Status Date

Tuesday, March 12, 2024

Serial Number

97442064

Mark Type

3000

Filing Date

Friday, June 3, 2022

Published for Opposition

Tuesday, March 12, 2024

Trademark Owner History

TransThera Sciences (Nanjing), Inc. - Owner At Publication

Classifications

5 Medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; drugs for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemico-pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biological preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; bulk medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biochemical medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for pharmaceutical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines in the nature of tablets for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders in the nature of capsule; injectable medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders

The mark consists of a spherical design formed by three stacked offset curved lines on the bottom and three stacked offset curved dotted lines on the top with the word "YOCHANRA" to the right of the design.
Color is not claimed as a feature of the mark.

Trademark Events

Mar 12, 2024

Official Gazette Publication Confirmation E-Mailed

Mar 12, 2024

Published For Opposition

Feb 21, 2024

Notification Of Notice Of Publication E-Mailed

Feb 21, 2024

Official Gazette Publication Confirmation E-Mailed

Feb 8, 2024

Notice Of Allowance Cancelled

Feb 7, 2024

Jurisdiction Restored To Examining Attorney

Feb 7, 2024

Petition To Director - Change Basis - Granted

Feb 6, 2024

Assigned To Petition Staff

Jan 10, 2024

Teas Petition To Amend Basis Received

Dec 12, 2023

Noa E-Mailed - Sou Required From Applicant

Nov 9, 2023

Teas Change Of Correspondence Received

Nov 9, 2023

Attorney/Dom.Rep.Revoked And/Or Appointed

Nov 9, 2023

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Nov 9, 2023

Applicant/Correspondence Changes (Non-Responsive) Entered

Nov 9, 2023

Teas Change Of Owner Address Received

Oct 17, 2023

Official Gazette Publication Confirmation E-Mailed

Oct 17, 2023

Published For Opposition

Sep 27, 2023

Notification Of Notice Of Publication E-Mailed

Sep 12, 2023

Withdrawal Of Attorney Granted

Sep 12, 2023

Teas Withdrawal Of Attorney Received

Sep 12, 2023

Approved For Pub - Principal Register

Aug 28, 2023

Teas/Email Correspondence Entered

Aug 28, 2023

Correspondence Received In Law Office

Aug 28, 2023

Assigned To Lie

Apr 14, 2023

Teas Response To Office Action Received

Mar 3, 2023

Notification Of Non-Final Action E-Mailed

Mar 3, 2023

Non-Final Action E-Mailed

Mar 3, 2023

Non-Final Action Written

Feb 25, 2023

Assigned To Examiner

Jun 14, 2022

Notice Of Design Search Code E-Mailed

Jun 13, 2022

New Application Office Supplied Data Entered

Jun 7, 2022

New Application Entered